← Back to Screener
Avita Medical, Inc. Common Stock (RCEL)
Price$4.18
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)5.05%
Price vs S&P 500 (4W)1.71%
VGM Score45.48
Market Capitalization$128.65M
All Metrics
Book Value / Share (Quarterly)$0.17
P/TBV (Annual)7.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.66%
Cash Flow / Share (Quarterly)$-1.05
Price vs S&P 500 (YTD)13.00%
Gross Margin (TTM)82.13%
Net Profit Margin (TTM)-62.67%
EPS (TTM)$-1.57
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-1.57
Revenue Growth (5Y)19.63%
EPS (Annual)$-1.74
ROI (Annual)-132.31%
Gross Margin (Annual)83.26%
Net Profit Margin (5Y Avg)-83.10%
Cash / Share (Quarterly)$0.46
Revenue Growth QoQ (YoY)3.98%
ROA (Last FY)-86.16%
Revenue Growth TTM (YoY)0.96%
EBITD / Share (TTM)$-1.28
ROE (5Y Avg)-303.00%
Operating Margin (TTM)-54.62%
Cash Flow / Share (Annual)$-1.07
P/B Ratio28.59x
P/B Ratio (Quarterly)74.59x
Net Income / Employee (Annual)$-215,000
EV / Revenue (TTM)2.30x
Net Interest Coverage (TTM)-8.71x
ROA (TTM)-78.92%
EPS Incl Extra (Annual)$-1.74
Current Ratio (Annual)0.57x
Quick Ratio (Quarterly)0.36x
3-Month Avg Trading Volume0.24M
52-Week Price Return-27.30%
Revenue / Employee (TTM)$320,100
Tangible BV / Share (Quarterly)$0.44
P/S Ratio (Annual)1.80x
Asset Turnover (Annual)1.27x
52-Week High$7.12
Operating Margin (5Y Avg)-83.16%
EPS Excl Extra (Annual)$-1.74
CapEx CAGR (5Y)6.99%
26-Week Price Return12.97%
Quick Ratio (Annual)0.44x
13-Week Price Return-12.55%
Total Debt / Equity (Annual)9.39x
Current Ratio (Quarterly)0.47x
Enterprise Value$166.48M
Revenue / Share Growth (5Y)14.79%
Asset Turnover (TTM)1.26x
Book Value / Share Growth (5Y)-44.92%
Revenue / Employee (Annual)$316,900
Inventory Turnover (Annual)1.69x
Pretax Margin (Annual)-67.83%
Cash / Share (Annual)$0.59
3-Month Return Std Dev71.93%
Gross Margin (5Y Avg)85.00%
Net Income / Employee (TTM)$-200,600
ROE (Last FY)-1374.64%
Net Interest Coverage (Annual)-7.73x
EPS Basic Excl Extra (Annual)$-1.74
Receivables Turnover (TTM)6.60x
Total Debt / Equity (Quarterly)9.39x
EPS Incl Extra (TTM)$-1.57
Receivables Turnover (Annual)6.86x
ROI (TTM)-102.95%
P/S Ratio (TTM)1.78x
Pretax Margin (5Y Avg)-83.00%
Revenue / Share (Annual)$2.57
Tangible BV / Share (Annual)$1.89
Price vs S&P 500 (52W)-51.67%
Year-to-Date Return21.16%
5-Day Price Return-4.57%
EPS Normalized (Annual)$-1.74
ROA (5Y Avg)-47.00%
Net Profit Margin (Annual)-67.85%
Month-to-Date Return-3.46%
Cash Flow / Share (TTM)$-1.31
EBITD / Share (Annual)$-1.44
Operating Margin (Annual)-59.40%
LT Debt / Equity (Annual)9.39x
ROI (5Y Avg)-48.07%
LT Debt / Equity (Quarterly)9.39x
EPS Basic Excl Extra (TTM)$-1.57
P/TBV (Quarterly)24.15x
P/B Ratio (Annual)74.59x
Inventory Turnover (TTM)1.78x
Pretax Margin (TTM)-62.68%
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)-20.81%
Beta1.86x
Revenue / Share (TTM)$2.37
ROE (TTM)-337.90%
52-Week Low$3.22
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.35est. -0.29
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.09
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RCELAvita Medical, Inc. Common Stock | C | C | C | $4.18 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Avita is a medical device company focused on the RECELL system, a proprietary burn treatment technology that creates Spray-on Skin from small patient samples in approximately 30 minutes, reducing the need for traditional skin grafts. The FDA-approved system is used across most of the nation's 140 burn centers and has expanded indications for soft-tissue reconstruction. While holding approvals in multiple countries, Avita focuses primarily on the US market, though international sales—particularly in Japan—are growing.